Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

National Notifiable Infectious Diseases and Conditions: United States

TABLE 6. Reported cases of notifiable diseases and rates per 100,000, by race*, excluding U.S. territories - - United States, 2017
Disease American Indian or
Alaska Native
Asian or Pacific
Islander
Black White Other Race Race not stated Total
No. Rate No. Rate No. Rate No. Rate No. No. No.
Anthrax
Arboviral diseases
Chikungunya virus disease 1 0.02 78 0.37 3 0.01 21 0.01 11 42 156
Eastern equine encephalitis virus disease
Neuroinvasive S S S S S S S S S S 5
Non-neuroinvasive
Jamestown Canyon virus disease
Neuroinvasive 1 0.02 38 0.01 3 16 58
Non-neuroinvasive S S S S S S S S S S 17
La Crosse virus disease
Neuroinvasive 1 0.00 56 0.02 1 5 63
Non-neuroinvasive
Powassan virus disease
Neuroinvasive 18 0.01 15 33
Non-neuroinvasive S S S S S S S S S S 1
St. Louis encephalitis virus disease
Neuroinvasive S S S S S S S S S S 6
Non-neuroinvasive S S S S S S S S S S 5
West Nile virus disease
Neuroinvasive 11 0.23 21 0.10 99 0.22 1,064 0.42 62 168 1,425
Non-neuroinvasive 6 0.13 9 0.04 21 0.05 498 0.20 29 109 672
Western equine encephalitis virus disease
Neuroinvasive
Non-neuroinvasive
Babesiosis
Total 10 0.35 59 0.35 39 0.12 1,511 0.76 98 651 2,368
Confirmed 7 0.24 48 0.28 34 0.10 1,264 0.64 94 547 1,994
Probable 3 0.10 11 0.06 5 0.01 247 0.12 4 104 374
Botulism
Total 4 0.09 15 0.07 5 0.01 105 0.04 7 41 177
Foodborne S S S S S S S S S S 19
Infant † 11 4.48 5 0.74 89 3.03 4 28 137
Other (wound & unspecified) S S S S S S S S S S 21
Brucellosis 2 0.04 6 0.03 7 0.02 84 0.03 6 35 140
Campylobacteriosis 574 12.24 1,859 8.76 3,391 7.39 41,482 16.34 4,505 15,726 67,537
Chancroid § S S S S S S S S S S 7
Chlamydia trachomatis infection § 19,770 421.62 27,956 131.80 475,496 1,036.30 552,963 217.76 112,699 519,685 1,708,569
Cholera S S S S S S S S S S 10
Coccidioidomycosis ¶ 203 8.46 504 5.08 489 3.46 4,587 4.37 1,071 7,510 14,364
Cryptosporidiosis
Total 79 1.68 164 0.77 986 2.15 7,937 3.13 488 1,760 11,414
Confirmed 62 1.32 128 0.60 751 1.64 5,447 2.15 343 1,312 8,043
Probable 17 0.36 36 0.17 235 0.51 2,490 0.98 145 448 3,371
Cyclosporiasis 1 0.02 21 0.10 44 0.11 826 0.36 44 258 1,194
Dengue virus infections **
Dengue 1 0.02 145 0.68 15 0.03 130 0.05 22 124 437
Dengue-like illness S S S S S S S S S S 8
Severe dengue S S S S S S S S S S 9
Diphtheria
Ehrlichiosis and Anaplasmosis
Anaplasma phagocytophilum infection 33 0.79 41 0.21 26 0.06 3,921 1.60 199 1,542 5,762
Ehrlichia chaffeensis infection 11 0.26 19 0.10 37 0.08 1,123 0.46 37 415 1,642
Ehrlichia ewingii infection 40 0.02 1 4 45
Undetermined ehrlichiosis/anaplasmosis 5 0.12 2 0.00 187 0.08 21 54 269
Giardiasis 76 2.10 427 2.35 1,202 3.46 7,740 3.89 864 4,884 15,193
Gonorrhea § 7,661 163.38 7,541 35.55 221,377 482.47 169,576 66.78 31,460 117,993 555,608
Haemophilus influenzae, invasive disease
All ages, all serotypes 70 1.49 95 0.45 843 1.84 3,552 1.40 142 846 5,548
Age <5 years ††
Serotype b 3 0.78 3 0.09 20 0.13 1 6 33
Non-b serotype 15 3.91 3 0.23 49 1.44 92 0.62 8 22 189
Nontypeable 4 1.04 7 0.54 43 1.26 104 0.70 12 30 200
Unknown serotype 4 1.04 10 0.78 48 1.41 98 0.66 17 26 203
Hansen's disease 19 0.10 7 0.02 40 0.02 4 24 94
Hantavirus infection, non-hantavirus pulmonary syndrome S S S S S S S S S S 2
Hantavirus pulmonary syndrome 6 0.13 17 0.01 1 9 33
Hemolytic uremic syndrome post-diarrheal 3 0.07 11 0.05 13 0.03 261 0.11 17 33 338
Hepatitis §§
A, acute 13 0.28 123 0.58 306 0.67 2,310 0.91 184 429 3,365
B, acute 19 0.41 67 0.32 415 0.91 2,316 0.92 146 446 3,409
B, perinatal infection ¶¶ 15 3.01 2 0.15 6 0.10 1 7 31
C, acute 81 1.97 27 0.13 244 0.56 3,136 1.30 189 548 4,225
Confirmed 66 1.61 24 0.12 211 0.48 2,347 0.97 151 414 3,213
Probable 15 0.37 3 0.01 33 0.08 789 0.33 38 134 1,012
Human immunodeficiency virus diagnoses 178 3.80 870 4.10 14,956 32.60 9,292 3.66 8,642 33,938
Influenza-associated pediatric mortality *** 1 0.07 5 0.11 31 0.25 67 0.12 3 19 126
Invasive pneumococcal disease †††
All ages 381 13.06 247 2.01 3,289 8.72 11,753 6.19 500 3,610 19,780
Confirmed 380 13.03 245 1.99 3,262 8.65 11,673 6.15 492 3,568 19,620
Probable 1 0.03 2 0.02 27 0.07 80 0.04 8 42 160
Age <5 years †† 39 1.13 44 0.33 264 0.66 639 0.31 37 211 1,234
Confirmed 39 13.51 43 5.14 260 8.68 632 5.34 37 209 1,220
Probable 1 0.12 4 0.13 7 0.06 2 14
Legionellosis 28 0.60 103 0.49 1,579 3.44 4,706 1.85 215 827 7,458
Leptospirosis 1 0.03 9 0.05 4 0.01 32 0.02 9 17 72
Listeriosis 3 0.06 81 0.38 96 0.21 581 0.23 35 91 887
Lyme disease
Total 109 2.33 361 1.78 390 0.85 23,641 9.33 961 17,281 42,743
Confirmed 66 1.41 238 1.17 256 0.56 16,153 6.37 741 12,059 29,513
Probable 43 0.92 123 0.61 134 0.29 7,488 2.95 220 5,222 13,230
Malaria 4 0.09 121 0.57 1,335 2.91 244 0.10 71 281 2,056
Measles
Total 10 0.05 62 0.14 34 0.01 3 11 120
Indigenous 3 0.01 62 0.14 26 0.01 2 6 99
Imported 7 0.03 8 0.00 1 5 21
Meningococcal disease
All serogroups 9 0.04 52 0.11 222 0.09 15 55 353
Serogroups ACWY 3 0.01 21 0.05 68 0.03 3 12 107
Serogroup B 1 0.00 10 0.02 65 0.03 3 11 90
Other serogroups 9 0.02 9 0.00 2 5 25
Unknown serogroup 5 0.02 12 0.03 80 0.03 7 27 131
Mumps 56 1.19 1,599 7.54 409 0.89 2,530 1.00 312 1,203 6,109
Novel Influenza A virus infections 2 0.00 61 0.02 3 66
Pertussis 122 2.60 337 1.59 987 2.15 13,031 5.13 721 3,777 18,975
Plague S S S S S S S S S S 5
Poliomyelitis, paralytic
Poliovirus infection, nonparalytic
Psittacosis S S S S S S S S S S 5
Q fever
Total 6 0.03 4 0.01 127 0.05 10 46 193
Acute 5 0.02 2 0.00 104 0.04 9 33 153
Chronic 1 0.00 2 0.00 23 0.01 1 13 40
Rabies
Human S S S S S S S S S S 2
Rubella S S S S S S S S S S 7
Rubella, congenital syndrome † S S S S S S S S S S 5
Salmonellosis 399 8.51 1,845 8.70 4,634 10.10 34,011 13.39 3,318 10,078 54,285
Severe acute respiratory syndrome-associated coronavirus disease
Shiga toxin-producing Escherichia coli §§§ 64 1.36 226 1.07 399 0.87 5,854 2.31 419 1,710 8,672
Shigellosis 196 4.18 369 1.74 3,006 6.55 7,842 3.09 1,103 2,396 14,912
Smallpox
Spotted fever rickettsiosis
Total 122 2.68 31 0.15 134 0.29 4,298 1.70 141 1,522 6,248
Confirmed 5 0.11 5 0.01 108 0.04 3 55 176
Probable 117 2.57 31 0.15 129 0.28 4,190 1.66 138 1,467 6,072
Streptococcal toxic shock syndrome 9 0.08 61 0.19 250 0.15 16 36 372
Syphilis
Total, all stages § 857 18.28 2,762 13.02 33,974 74.04 48,505 19.10 7,617 7,852 101,567
Congenital † 14 18.34 14 5.70 359 53.10 474 16.11 22 35 918
Primary and secondary § 297 6.33 885 4.17 9,869 21.51 15,525 6.11 2,086 1,982 30,644
Tetanus 3 0.01 22 0.01 8 33
Toxic shock syndrome (other than Streptococcal) 1 0.01 3 0.01 14 0.01 1 11 30
Trichinellosis S S S S S S S S S S 15
Tuberculosis 110 2.35 3,273 15.43 1,958 4.27 3,453 1.36 157 154 9,105
Tularemia 24 0.51 3 0.01 6 0.01 155 0.06 6 45 239
Typhoid fever 4 0.09 196 0.92 54 0.12 66 0.03 47 52 419
Vancomycin-intermediate Staphylococcus aureus 25 0.06 63 0.03 7 14 109
Vancomycin-resistant Staphylococcus aureus S S S S S S S S S S 3
Varicella morbidity 63 1.77 508 2.80 557 1.47 5,454 2.64 393 1,800 8,775
Varicella mortality U U U U U U U U U U U
Vibriosis
Total 15 0.32 116 0.55 137 0.30 1,386 0.56 101 330 2,085
Confirmed 11 0.24 82 0.39 91 0.20 977 0.39 85 251 1,497
Probable 4 0.09 34 0.16 46 0.10 409 0.16 16 79 588
Viral hemorrhagic fevers
Crimean-Congo hemorrhagic fever virus
Ebola virus
Guanarito virus
Junin virus
Lassa virus
Lujo virus
Machupo virus
Marburg virus
Sabia virus
Yellow fever
Zika virus
Zika virus disease, congenital †,¶¶¶ S S S S S S S S S S 22
Zika virus disease, non-congenital 12 0.06 21 0.05 290 0.11 46 128 497
Zika virus infection, congenital †,¶¶¶ S S S S S S S S S S 17
Zika virus infection, non-congenital 1 0.02 27 0.13 146 0.32 189 0.07 101 177 641
  • —: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
  • U: Unavailable — The data are unavailable.
  • S: Suppressed
  • * Conditions with <25 cases reported in the year were not broken down by race.
  • † The rate is calculated using population less than 1 year of age.
  • § Race data were collected using current Office of Management and Budget (OMB) standards for race/ethnicity data and were mapped to bridged race categories.
  • ¶ Reportable in <25 states.
  • ** Total number of reported laboratory-positive dengue cases, including all confirmed cases [by anti-dengue virus (DENV) molecular diagnostic methods or seroconversion of anti-DENV IgM] and all probable cases (by a single, positive anti-DENV IgM).
  • †† The rate is calculated using population less than 5 years of age.
  • §§ Chronic hepatitis B and C data are not included in NNDSS tables but reported case counts are included in the annual Summary of Viral Hepatitis, published online by CDC's Division of Viral Hepatitis, available at https://www.cdc.gov/hepatitis/statistics/2016surveillance/index.htm.
  • ¶¶ The rate is calculated using population less than 2 years of age.
  • *** The rate is calculated using population less than 18 years of age.
  • ††† Includes drug resistant and susceptible cases of Invasive Pneumococcal Disease. This condition was previously named Streptococcus pneumoniae invasive disease and cases were reported to CDC using different event codes to specify whether the cases were drug resistant or in a defined age group, such as <5 years.
  • §§§ Includes Escherichia coli O157:H7 and Shiga toxin-positive Escherichia coli (including O157, non-O157, and not serogrouped).
  • ¶¶¶ Data reported to ArboNET using the national surveillance case definition for congenital Zika virus disease or infection (CSTE Position Statement 16-ID-01). Additional data reported to the US Zika Pregnancy Registry for outcomes of pregnancies with laboratory evidence of possible Zika virus infection are available at https://www.cdc.gov/pregnancy/zika/data/pregnancy-outcomes.html. Cases reported to the US Zika Pregnancy Registry might not meet the national surveillance case definition for congenital Zika virus disease or infection.

TOP